Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Trial Profile

A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca

Most Recent Events

  • 23 Oct 2018 Results of a retrospective analysis published in the American Journal of Cardiovascular Drugs
  • 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
  • 01 Feb 2018 Results evaluating the potential benefit of TA and pre-H ticagrelor treatment in patients enrolled in the ATLANTIC trial published in the American Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top